RAPAFLO(TM) (silodosin) Provides Rapid And Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief In As Little As Three Days RAPAFLO(TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produces rapid improvements of both irritative and obstructive urinary symptoms that were sustained for 12 weeks, according to data published in the June issue of The Journal of Urology.
Source: www.medicalnewstoday.comShedding Light On The Mechanisms Of Early Stage Liver Reperfusion Injury Reperfusion of a previously ischemic tissue is associated with additional injury leading to structural and functional alterations in many organs including the liver. The injury induced during reperfusion is has evolved into a biphasic pattern consisting of an early stage of reoxygenation and a delayed phase.
Source: www.medicalnewstoday.comTAU Investigates MicroRNA And Its Role In Human Disease Just as scientists finished sequencing the human genome, they got a new surprise. Inside the genetic pathway, where DNA produces proteins to sustain life, they found microRNA. These tiny ubiquitous molecules have opened a new research channel in biology, allowing scientists to more closely examine what causes genetic diseases, and what makes our cells tick.
Source: www.medicalnewstoday.comTransatlantic Alliance Supports Breast Cancer Research A new transatlantic alliance has formed in the global battle against breast cancer, with the US-based international grass-roots movement Susan G. Komen for the Cure® giving its support to the groundbreaking IMPAKT Breast Cancer Conference, co-organized by the Breast International Group (BIG) and the European Society for Medical Oncology (ESMO). Susan G. Komen for the Cure is the world's largest source of non-profit funds for the fight against breast cancer.
Source: www.medicalnewstoday.comPhase 3 Data On VIVUS' Qnexa To Be Presented At 17th European Congress On Obesity VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that data from the phase 3 EQUATE trial (OB-301) of Qnexa™ in obese patients will be presented at the 17th annual European Congress on Obesity (ECO) in Amsterdam, The Netherlands.
Source: www.medicalnewstoday.comCurrent Multi-Omponent Vaccines May Need Reworking, According To Study Current strategies for designing vaccines against HIV and cancers, for instance, may enable some components in multi-component vaccines to cancel the effect of others on the immune system, eliminating their ability to provide protection, according to an article to be published shortly in the Proceedings of the National Academy of Sciences (PNAS).
Source: www.medicalnewstoday.comHydroxycut Products Dietary
supplements are associated with serious liver injury, including liver failure, seizures, cardiovascular disorders, and rhabdomyolysis.
Source: www.fda.govNanoTech 2009 At Houston, May 3-7, 2009 For the first time since its inception more than a decade ago, the world's largest international nanotechnology conference, expo and trade show is coming to Houston May 3-7 at the George R. Brown Convention Center, and University of Houston researchers will be attending in full force. The Nano Science and Technology Institute's NanoTech 2009 has traditionally been held on the East and West coasts.
Source: www.medicalnewstoday.comEarly Detection Is Key In Dementia The leader of dementia research in CSIRO's Preventative Health National Research Flagship, Dr Cassandra Szoeke, says the report highlights the challenge the nation faces with the number of dementia sufferers predicted to double to 465,000 by 2030. "About 80 per cent of dementia in Australia is caused by Alzheimer's disease," Dr Szoeke, says.
Source: www.medicalnewstoday.comConsumers More Likely To Identify Healthy Food Using Traffic Light Nutrition Labels Consumers are five times more likely to identify healthy food when they see colour-coded traffic light nutrition labels than when labels present the information numerically by showing what percentage of the recommended daily nutrient intake each portion provides, new research finds.
Source: www.medicalnewstoday.com
# posted by Network @ 12:57 AM
